First Trust NASDAQ Smart Grid ETF vs Natera Inc. Common Stock — how do they compare? First Trust NASDAQ Smart Grid ETF trades at $173.79 (market cap $12.09B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.7× First Trust NASDAQ Smart Grid ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, First Trust NASDAQ Smart Grid ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Smart Grid ETF for 14 Days and Natera Inc. Common Stock for 0 Days on average.
| GRID | NTRA | |
|---|---|---|
Market Cap | $12.09B | $57.03B |
Volume | 561,107 | 1,131,157 |
Sector | Sector/Thematic | Health |
52-Week High | $199.80 | $425.64 |
52-Week Low | $146.51 | $179.42 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | — | $56.18B |
Signals from Pluang's Aura AI — not financial advice
GRID trades at $179.25, up 0.31% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock is positioned in the smart grid infrastructure sector, benefiting from AI-driven power buildout investments. Recent news highlights its exposure to infrastructure modernization and AI energy demand, though key financial ratios are not disclosed in the provided data.
Outlook is mixed: technicals suggest caution, but thematic tailwinds from AI infrastructure spending offer growth potential. Risks include sector competition and execution challenges. Investors should weigh near-term technical weakness against long-term infrastructure investment trends.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
First Trust NASDAQ Smart Grid Infrastructure ETF seeks to track companies involved in smart grid and electricity infrastructure. Its holdings include businesses related to power networks, energy management, and grid technologies.
Read more on GRID →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →